Sore Throat News and Research

RSS

European CHMP issues positive opinion to Vertex's KALYDECO for treatment of CF

Vertex Pharmaceuticals Incorporated announced today that the European Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion by consensus recommending the approval of KALYDECO (ivacaftor) for people with cystic fibrosis (CF) ages 6 and older who have at least one copy of the G551D mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.

25 May 2012

Linagliptin safe and effective for African American patients with type 2 diabetes

Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company today announced Phase 3 study results for linagliptin 5 mg once-daily, which showed significant hemoglobin A1c (HbA1c or A1C) reduction of 0.88 percent compared to 0.24 percent in the placebo group (p=0.0002) at 24 weeks in black or African American adult patients with type 2 diabetes whose blood sugar was not adequately controlled.

25 May 2012

Vertex reports interim data from VX-809 and KALYDECO combination Phase 2 study for cystic fibrosis

Vertex Pharmaceuticals Incorporated announced today an interim analysis of data from an ongoing Phase 2 study of VX-809 and KALYDECO (ivacaftor) that showed significant improvements in lung function (FEV1) among adults with cystic fibrosis (CF) who have two copies.

7 May 2012

AstraZeneca introduces DUTOPROL for hypertension

AstraZeneca today announced the availability of DUTOPROL (metoprolol succinate extended release/hydrochlorothiazide) Tablets, the first and only once-daily antihypertensive agent that contains the active ingredient of TOPROL-XL (metoprolol succinate) plus a low-dose diuretic that provides proven blood pressure lowering at 24 hours.

12 Apr 2012

Needle-free vaccine shows promise against RSV in children

Researchers at the University of Saskatchewan are closing in on a needle-free vaccine for respiratory syncytial virus (RSV), a major cause of respiratory illness in children under two years of age.

30 Mar 2012

MedImmune receives FDA approval for FluMist Quadrivalent vaccine

FluMist Quadrivalent, a vaccine to prevent seasonal influenza in people ages 2 years through 49 years, has been approved today by the U.S. Food and Drug Administration. FluMist Quadrivalent is the first influenza vaccine to contain four strains of the influenza virus, two influenza A strains and two influenza B strains.

27 Mar 2012

Valeant signs agreement to acquire Natur Produkt

Valeant Pharmaceuticals International, Inc. announced today that Valeant has signed an agreement to acquire Natur Produkt International, JSC, a specialty pharmaceutical company in Russia.

26 Mar 2012

Air emissions near natural gas drilling sites may contribute to health problems

In a new study, researchers from the Colorado School of Public Health have shown that air pollution caused by hydraulic fracturing or fracking may contribute to acute and chronic health problems for those living near natural gas drilling sites.

19 Mar 2012

Study examines how symptoms presented online influence people's reactions to medical conditions

Maybe you've had a reoccurring sore throat or frequent headaches. Perhaps the pain in your leg won't go away. In the past, you might have gone to a doctor's office to diagnose symptoms.

13 Mar 2012

Pfizer’s Prevnar 13 Phase 3 study for pneumococcal disease meets all study endpoints

Pfizer Inc. announced today that data from a Phase 3 study of Prevnar 13 (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]) met all study endpoints, showing immunogenicity and establishing a safety profile in children and adolescents aged 5 through 17 years.

12 Mar 2012

Lilly, Boehringer Ingelheim announce availability of Jentadueto tablets

Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company today announced Jentadueto (linagliptin/metformin hydrochloride) tablets are now available by prescription in many leading chain and independent pharmacies across the U.S.

8 Mar 2012

FDA approves MedImmune's FluMist Quadrivalent vaccine

MedImmune today announced that the U.S. Food and Drug Administration (FDA) has approved FluMist Quadrivalent (Influenza Vaccine Live, Intranasal) for prevention of influenza.

29 Feb 2012

Maintaining differential diagnosis inclusive of infectious etiology may help save children's life

Neurologic tics and obsessive-compulsive behaviors caused by a bacterial infection in children were once thought to occur exclusively in PANDAS (Pediatric Autoimmune Disease Associated with Streptococcus infections).

23 Feb 2012

AstraZeneca launches ARIMIDEX Direct to help cancer patients

AstraZeneca today announced its first-ever direct-to-patient program offering patients with a valid prescription for ARIMIDEX or anastrozole the opportunity to have the brand ARIMIDEX delivered directly to their home by Express Scripts, a specialty pharmacy services provider, for $40 per month, including shipping.

17 Feb 2012

Prestige Brands third quarter net revenues increase 17.3% to $106.3M

Prestige Brands Holdings, Inc. today announced results for the fiscal 2012 third quarter ended December 31, 2011, including net revenues of $106.3 million, an increase of 17.3% over the prior year's comparable quarter of $90.6 million.

9 Feb 2012

Asian bird flu update for Ferbruary 2012

Health workers in Nepal are to cull thousands of chickens following the discovery of the H5N1 strain of bird flu in the southeastern part of the Himalayan country.

6 Feb 2012

Prestige acquires 15 brands from GSK

Prestige Brands Holdings, Inc. today announced that it has completed its previously announced purchase of fifteen of the seventeen brands it agreed to acquire from GlaxoSmithKline (GSK).

1 Feb 2012

Boehringer Ingelheim, Lilly receive FDA approval for Jentadueto to treat type 2 diabetes

Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company today announced the U.S. Food and Drug Administration (FDA) has approved Jentadueto (linagliptin/metformin hydrochloride) tablets, a new tablet combining the dipeptidyl peptidase-4 (DPP-4) inhibitor, linagliptin, and metformin.

31 Jan 2012

Non-smoking, non-drinking transplant patients more likely to develop head and neck cancer

Transplant patients who develop head and neck cancer are more likely to be non-smokers and non-drinkers, and less likely than their non-transplant counterparts to survive past one year of diagnosis, according to a new study from Henry Ford Hospital in Detroit.

30 Jan 2012

Lansoprazole increases risk of sore throats, respiratory problems in children with asthma

Adding the acid reflux drug lansoprazole to a standard inhaled steroid treatment for asthma does not improve asthma control in children who have no symptom of acid reflux, according to a new study funded in part by the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health. Lansoprazole therapy slightly increased the risk of sore throats and other respiratory problems in children, however.

25 Jan 2012